key: cord-0861647-mzyxiknu
authors: Kathuria-Prakash, Nikhita; Mosaferi, Tina; Xie, Mindy; Antrim, Lauren; Angell, Trevor E.; In, Gino K.; Su, Maureen A.; Lechner, Melissa G.
title: COVID-19 Outcomes of Patients with Differentiated Thyroid Cancer: A Multi-Center Los Angeles Cohort Study
date: 2021-01-04
journal: Endocr Pract
DOI: 10.1016/j.eprac.2020.12.013
sha: 605d46095513bbd4ce247368624b20ccdd3c03e4
doc_id: 861647
cord_uid: mzyxiknu

OBJECTIVE: Cancer may be a risk factor for worse outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. However, there is significant variability across cancer types in the extent of disease burden and modalities of cancer treatment that may impact morbidity and mortality from COVID-19. Therefore, we evaluated COVID-19 outcomes in patients with a history of differentiated thyroid cancer (DTC). METHODS: This is a retrospective cohort study of patients with a history of DTC and SARS-CoV2 infection from two academic Los Angeles healthcare systems. Demographic, thyroid cancer and treatment data were analyzed for association with COVID-19 outcomes. RESULTS: Of 21 patients with DTC and COVID-19, 8 were hospitalized (38.1%) and 2 died (9.5%) from COVID-19. Thyroid cancer initial disease burden and extent, treatment, or current response to therapy (e.g. excellent vs. incomplete) were not associated with COVID-19 severity among DTC patients. However, older age and the presence of a comorbidity other than DTC were significantly associated with hospitalization for COVID-19 (p=0.047 and p=0.024, respectively). COVID-19 attributed hospitalization and mortality in DTC patients was lower than previously reported in cancer patients, but similar to patients with non-thyroid malignancies in these centers. CONCLUSIONS: These data suggest that among patients with DTC, advanced age and comorbid conditions are significant contributors to the risk of hospitalization from SARS-CoV2 infection, rather than factors associated with thyroid cancer diagnosis, treatment, or burden of disease. This multi-center report of clinical outcomes provides additional data to providers to inform DTC patients regarding their risk of COVID-19.

(9.5%) from COVID-19. Thyroid cancer initial disease burden and extent, treatment, or current 48 response to therapy (e.g. excellent vs. incomplete) were not associated with COVID-19 severity 49 among DTC patients. However, older age and the presence of a comorbidity other than DTC 50 were significantly associated with hospitalization for COVID-19 (p=0.047 and p=0.024, respec-51 tively). COVID-19 attributed hospitalization and mortality in DTC patients was lower than pre-52 viously reported in cancer patients, but similar to patients with non-thyroid malignancies in these 53

Conclusions: These data suggest that among patients with DTC, advanced age and comorbid 55 conditions are significant contributors to the risk of hospitalization from SARS-CoV2 infection, 56 rather than factors associated with thyroid cancer diagnosis, treatment, or burden of disease. This 57 multi-center report of clinical outcomes provides additional data to providers to inform DTC pa-58 tients regarding their risk of Introduction 62

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is a novel coronavirus 63 that produces a syndrome of respiratory symptoms, fever, and multiorgan dysfunction called 64 coronavirus disease-19 (COVID-19) 1 . The presentation of COVID-19 can range from asympto-65 matic infection to life-threatening, multiorgan dysfunction requiring ICU level care, mechanical 66 ventilation, renal replacement therapy, and death. Beginning in late 2019, SARS-CoV2 infection 67 has become the source of a global pandemic with more than 66 million infected and more than 68 1.5 million COVID-19 attributed deaths 1 . Important prior studies have identified risk factors for 69 worse outcomes from COVID-19, including older age, cardiovascular and cerebrovascular dis-70 ease, pulmonary disease, and diabetes mellitus 2 . Studies evaluating the potential impact of a his-71 tory of cancer on COVID-19 severity and outcomes have shown mixed results, with some show-72 ing increased mortality in patients with malignancy and others showing no differences in mor-73 tality between those with and without malignancy [3] [4] [5] [6] [7] [8] . Furthermore, studies to assess the interplay 74 between COVID-19 and specific malignancies are lacking. 75

Thyroid cancer is the most common endocrine malignancy, with over 50,000 new cases 76

per year and over 800,000 affected individuals in 2017 in the United States alone 9 . A recent sur-77 vey of patients with a history of thyroid cancer showed high concern over the COVID-19 out-78 break and its impact on their life 10 . In contrast to many other solid malignancies, differentiated 79 thyroid cancer (DTC) is treated primarily with surgery, thyroid hormone suppression, and, some-80 times, radioactive iodine ablation. Patients are rarely treated with conventional chemotherapy or 81 myelosuppressive agents that are more likely to cause immunosuppression. Additionally, disease 82 specific survival in DTC is generally excellent 11 . However, thyroid cancer can compromise the 83 airways because of the close proximity of the thyroid gland to the trachea, may metastasize to the 84 J o u r n a l P r e -p r o o f lungs, and may alter immune responses through tumor-mediated immunosuppression 12-14 . De-85 spite significant concern among patients with thyroid cancer, few studies have been published 86 examining the outcomes of patients with a history of thyroid cancer who contract In the present study, we report the outcomes of SARS-CoV2 infection in patients with a 88 history of DTC who received care at two academic Los Angeles healthcare systems. Further-89 more, we evaluate thyroid cancer-related and independent patient factors associated with hospi-90 talization and mortality from COVID-19 in this population. These data can provide DTC-specific 91 guidance to providers and DTC patients on the risks of severe We performed a manual chart review through physician documentation for all identified 106 patients to extract demographic data (age, sex), comorbidities (pre-existing diabetes mellitus, 107 body mass index (BMI), and smoking status. Lung disease was defined as a diagnosis of chronic 109 lung pathology, such as asthma, chronic obstructive pulmonary disease (COPD, including em-110 physema), interstitial lung disease, previously diagnosed pulmonary embolism currently on ther-111 apeutic anticoagulation (not prophylaxis or therapeutic doses as part of COVID treatment), or 112 pulmonary aspergillosis. Cardiovascular disease was defined as a history of myocardial infarc-113 tion, arrhythmia, coronary artery disease, peripheral vascular disease, heart failure, or cerebro-114 vascular accident. Liver disease was defined as cirrhosis, alcoholic liver disease, chronic hepati-115 tis, and non-alcoholic fatty liver disease. Chronic kidney disease was defined as having an eGFR 116 less than 60 mL/min/1.73m 2 . Use of chronic steroids was considered taking any dose of oral 117 steroids daily or every other day, excluding steroids taken intermittently, such as for flares of a 118

For thyroid cancer history, data collection included date of diagnosis, primary tumor size 120 and histology, lymph node involvement, extrathyroidal spread (none, minimal, or gross), and J o u r n a l P r e -p r o o f (5 patients) edition stage I or II disease, but this was not evaluated as a predictor of COVID-19 131 outcomes due to recent changes in patient stage classification (2016 revision to AJCC 8 th ed.) 132 and overall low disease-specific mortality in DTC 11 . 133

We identified the following COVID-19 related outcomes for each patient through review 134 of the EMR: hospitalization, supplemental oxygen administration (including nasal cannula, high Descriptive statistics were used to evaluate demographic metrics, thyroid cancer metrics, 147

and COVID-19 outcomes in our cohort of DTC patients. Our pre-specified primary clinical out-148 come was the frequency of hospitalization from COVID-19. years) and 17 (80%) were female (Table 1) . Overall, 57.1% of patients had one or more comor-164 bidity other than DTC (Table 1) . Comorbidities present included type 2 diabetes mellitus (7/21, 165 33%), lung disease (4/21, 19%), cardiovascular disease (2/21, 9.5%), and chronic steroid therapy 166

(2/21, 9.5%). None had a history of chronic liver or kidney disease and one was a prior smoker 167 (Table 1) . Using BMI measurement, 28.6% of the patients were normal weight, 38.1% were 168 overweight (BMI 25.0-29.9), and 33.3% were obese (BMI >30.0) ( Table 1) . 169

All patients had papillary thyroid cancer ( Table 2 ). The primary tumor size was <1 cm in 170 6 patients (28%), 1-2 cm in 6 patients (28.6%), and greater than 2 cm in 5 patients (23.8%); and 171 unknown in 4 (19%) patients. Histologic subtypes were classical (61.9%), follicular (23.8%), and 172 tall cell, cribriform, and unknown (4.8% each). Tumors were intrathyroidal in 15/21 patients 173 (71.4%) and lymph node metastasis was present at diagnosis in 10/21 patients (47.6%). All pa-174 tients underwent total thyroidectomy. Sixty-two percent of patients received RAI treatment. 175 J o u r n a l P r e -p r o o f ATA risk of recurrence at diagnosis was classified as low in 10 (47.6%) patients, intermediate in 176 5 (23.8%) patients, and high in 1 patient (4.8%). Initial recurrent risk was unable to be deter-177 mined from the EMR in 5 patients. The 2015 ATA dynamic risk stratification (DRS) 15 for all 178 patients within the preceding six months was assessed as an indicator of thyroid cancer disease 179 activity. Fifteen of 21 patients had excellent disease response (71.4%) and 2 patients (9.5%) each 180 had indeterminate, biochemically incomplete, or structurally incomplete responses ( sociation between the severity of COVID-19 and recurrence risk. The patients included had a 202 median of 10.8 years between diagnosis of thyroid cancer and diagnosis of COVID-19, ranging 203 from 3 months (0.33 years) to 36 years between diagnoses. Five of 21 patients were within 5 204 years of initial thyroid cancer diagnosis, including 1 of 8 who were hospitalized for Interestingly, more patients who received a cumulative RAI dose of ≥100mCi were hospitalized 206 for COVID-19 than those who received no RAI or lower RAI doses ( Table 2) , but this associa-207 tion was not statistically significant in our cohort. Regarding DTC disease status and response to 208 therapy near the time of COVID-19 diagnosis, we found no association between hospitalization 209 and ATA dynamic risk stratification category. Six patients with excellent dynamic risk stratifica-210 tion were hospitalized (40%), compared to 1 patient with indeterminate response (50%) and 1 211 patient with a structurally incomplete response (50%) ( Table 2) . Of two patients with COVID-19 212 attributed deaths, one had an excellent response to treatment and one had a structurally incom-213 plete response (Supplemental Table 1 ). 214 215

We then evaluated non-DTC clinical parameters previously associated with increased risk 217 of poor outcomes in COVID-19, including older age, male sex, and medical comorbidities. Older 218 age was significantly associated with hospitalization from COVID-19 (p = 0.047). Patients who 219 were over 60 years of age, compared to younger patients, more often required hospitalization 220 (60% vs. 18%), supplemental oxygen (40% vs. 18%), mechanical ventilation (20% vs. 9%) and 221 J o u r n a l P r e -p r o o f vasopressor support (20% vs. 9%) (Supplemental Table 2 ). Furthermore, COVID-19 attributed 222 mortality was greater in patients over 60 years of age (20% vs. no deaths in patients 60 years old 223 and younger). Male patients, compared to females, in our cohort were more likely to be hospital-224 ized for COVID-19 (50% vs. 35.3%) and die from COVID-19 (25% vs. 6%), though these did 225 not reach statistical significance. Additionally, over half (4/7, 57.1%) of patients with a BMI>30 226 required hospitalization, compared to only 28.6% (4/14) with a lower BMI. In patients with 227 DTC, those with type 2 diabetes mellitus, lung disease, or cardiovascular disease were more like-228 ly to be hospitalized for COVID-19 ( The syndrome of COVID-19 resulting from SARS-CoV2 infection is currently the cause 236 of unprecedented hospitalizations, acute respiratory distress syndrome (ARDS) requiring inten-237 sive care, and mortality worldwide 1 . A history of cancer has been suggested as a risk factor for 238 poor clinical outcomes from SARS-CoV2 infection, including increased risk of hospitalization 239 and mortality 3,5,16 . We report the clinical outcomes of SARS-CoV2 infection in patients with dif-240 ferentiated thyroid cancer from two large academic medical centers in the United States, with the 241 largest cohort of this population to date. 242

The rate of hospitalization for COVID-19 in DTC patients was 38.1% and 2/21 patients 243 (9.5%) had COVID-19 attributed death. We found no association between worse outcomes and 244 J o u r n a l P r e -p r o o f thyroid cancer disease extent, treatment, or response to therapy. On the other hand, older age and 245 pre-existing diabetes mellitus or cardiopulmonary disease were significantly associated with in-246 creased COVID-19 hospitalization. These findings are consistent with previous studies in more 247 general populations suggesting that advanced age, diabetes mellitus, and pulmonary and cardio-248 vascular disease are risk factors for poor clinical outcomes from SARS-CoV2 infection [17] [18] [19] . Data 249 from the Centers for Disease Control suggested that individuals over age 65 were five times 250 more likely to be hospitalized and 90 times more likely to die from COVID-19 compared to in-251 dividuals 18-29 years of age in the United States 20 . Additionally, diabetes mellitus has been as-252 sociated with a three-fold higher risk of hospitalization from COVID-19, potentially due to im-253 mune dysregulation 17, 18 . The presence of multiple comorbidities (including diabetes mellitus, 254 chronic kidney disease, obesity, coronary artery disease, stroke, and asthma or COPD) increased 255 further the risk of hospitalization from COVID-19 (4.5 fold with 2 and 5 fold with ≥3 comorbidi-256 ties) 17 . 257

While the aim of this study was to evaluate predictors of poor COVID-19 outcomes with-258 in DTC patients, the rates of hospitalization and death seen in these patients can be related to the 259 larger population of SARS-CoV2 infected patients in Los Angeles during the study period. 260

Compared to the frequency of COVID-19 hospitalization in DTC patients (38.1%), the rate of 261 hospitalization in patients with non-thyroid malignancies across the UCLA and LAC+USC 262 health systems was 37.7% (89/236; p=ns) and in a recently reported cohort from Los Angeles 263 (12.2%) 23 . DTC patients also had a rate of COVID-19 attributed death comparable to that of pa-264 tients with non-thyroid malignancy at these sites (2/21, 9.5% vs. 18/236, 7.6%, p=ns). Matched 265 data to directly compare hospitalization and mortality rates in non-cancer patients with SARS-266

CoV2 at these sites were not available. However, the rate of hospitalization for a general popula-267 J o u r n a l P r e -p r o o f tion over 60 years of age within the UCLA health system in Los Angeles was 387/1343 (28.8%). 268 COVID-19 mortality was lower in the overall population of Los Angeles (2.4%) compared to our 269 cohort of DTC patients, but similar for the subset of patients aged ≥60-65 years of age (13-270 15.6%) 21, 22 . Perhaps most importantly, the hospitalization and mortality rates seen in our cohort 271 of DTC patients was much less than that previously reported for cancer patients. Petrilli et al. 272 reported that 295/403 (73%) patients with cancer vs. 2446/4876 (50.1%) without cancer were 273 hospitalized among a cohort testing positive for SARS-CoV2 at ambulatory and emergency room 274 sites in New York, and found an increased risk of COVID-19-associated death among cancer 275 patients (HR 1.31, 1.05-1.62, p=0.02) 16 . Another study from New York found a lower case-276 fatality rate among cancer patients with COVID-19, but this was still significantly higher than 277 age-adjusted mortality for non-cancer patients in New York at the same time. Finally, in a meta-278 analysis by Saini et al. including 52 studies and 18,650 patients with COVID-19, the mortality 279 rate among cancer patients with SARS-CoV2 infection was 25.6% (95% confidence interval 280 22.0%-29.5%) 3, 5 . The lower rates of hospitalization and death seen in our cohort of DTC pa-281 tients is likely multifactorial, and may include improved overall outcomes of SARS-CoV2 infec-282 tion through the summer of 2020, a cancer population comprised of more patients not on active 283 treatment or cytotoxic therapy, and regional differences in the availability of testing. Most pa-284 tients in this cohort had COVID-19 between April and June, 2020, corresponding to the first two 285 peaks of the disease in the Los Angeles region. 286

There are several limitations that must be considered in the interpretation of these data. 287

While this is the largest cohort of DTC patients with SARS-CoV2 infection reported to date, the 288 relatively small sample size limits our statistical power. Potential important risk factors, such as 289 RAI exposure, may warrant analysis in larger studies. Interestingly, our data showed worse 290 J o u r n a l P r e -p r o o f COVID-19 outcomes in those DTC patients that had received cumulative RAI doses greater than 291 100mCi, though this difference did not reach statistical significance. Radioactive iodine therapy, 292 which is widely used for adjuvant treatment of DTC patients, has known side effects including 293 risk of secondary malignancies, sialoadenitis, and pulmonary fibrosis that occur with increased 294 frequency at higher cumulative doses 24,25 . This cohort of DTC patients did not contain patients 295 treated with lobectomy or receiving systemic therapies (e.g. chemotherapy, kinase inhibitors, 296 immunotherapy) for metastatic disease, and therefore may not be generalizable to all patients. In 297 addition, no thyroid cancer patients had lung metastases, which may be expected to worsen out-298 comes from COVID-19 due to decreased baseline pulmonary function. Given the retrospective 299 nature of our study, complete thyroid cancer staging and risk assessment information was miss-300 ing for some patients. Furthermore, charts were manually abstracted for clinical outcomes, in-301 cluding hospitalization and death due to COVID-19. When a clear designation of COVID-19 as 302 the cause of clinical outcomes was not present in the medical record, established manifestations 303 of COVID-19 were used to classify patients, and this is a potential source of bias that may have 304 led to overestimation of hospitalization and mortality. 305 306

These data suggest that a history of DTC, in and of itself, is likely not a significant con-308 tributor to the risk of hospitalization from SARS-CoV2 infection, whereas established risk fac-309 tors of increased age, underlying cardiopulmonary disease, and diabetes mellitus, are likely more 310 important in determining patient outcomes. Given the significant concern reported by thyroid 311 cancer patients regarding COVID-19, this multi-center report of clinical outcomes can provide 312 J o u r n a l P r e -p r o o f Highlights • In a cohort of 21 patients with differentiated thyroid cancer with COVID-19 at two large academic medical centers, we report a hospitalization rate of 38.1% and a mortality rate of 9.5%. In this cohort of DTC patients, the hospitalization and mortality rates were lower than previously reported for cancer patients, but similar to that for patients with non-thyroid malignancies treated at these centers and higher than the general population in this region.

• Thyroid cancer initial disease burden and extent, treatment, or current response to therapy (e.g. excellent vs. incomplete) were not associated with COVID-19 severity among DTC patients.

• Factors associated with hospitalization for COVID-19 were increased age, underlying cardiopulmonary disease, and diabetes mellitus.

WHO Coronavirus Disease (COVID-19) Dashboard

Epidemiological, comorbidity factors with severity and 321 prognosis of COVID-19: a systematic review and meta-analysis

Mortality in patients with cancer and 324 coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Determinants of COVID-19 disease severity 327 in patients with cancer

Case Fatality Rate of Cancer Patients with COVID-329 19 in a New York Hospital System

Patients with Cancer Appear More Vulnerable to SARS-332

CoV-2: A Multicenter Study during the COVID-19 Outbreak

Clinical impact of COVID-19 on patients 335 with cancer (CCC19): a cohort study

Cancer increases risk of in-hospital death from COVID-19 in 338 persons <65 years and those not in complete remission

Cancer Stat Facts: Thyroid Cancer. National Institutes 341 of Health2020

Cancer Care During COVID-19 Era: The Quality 343 of Life of Patients With Thyroid Malignancies

Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to 347

Prognostic indicators of outcomes in patients 350 with distant metastases from differentiated thyroid carcinoma

Thyroid cancer invasion of neck structures: epidemiology, 353 evaluation, staging and management. Curr Opin Otolaryngol Head Neck Surg

BRAF V600E in 356 papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression 357 suppressive immune cell infiltration

American Thyroid Association Management Guidelines for Adult 360

Factors associated with hospital admission and 363 critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective 364 cohort study

Risk Factors for COVID-19-associated 366 hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral 367

Risk Factor Surveillance System

Diabetes, infection risk and COVID-19

Should atrial fibrillation be considered a 371 cardiovascular risk factor for a worse prognosis in COVID-19 patients?

Coronavirus Disease 2019 Case Surveillance -United States

LA County COVID-19 Surveillance Dashboard

COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center

Cancer Treatment and Research Communications

Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism

Complications of radioactive iodine treatment of thyroid carcinoma